Dexcom (DXCM) 47th Annual Raymond James Institutional Investor Conference summary

Key strategic priorities and leadership changes

• Focus on being the premier glucose sensing solution, enhancing customer experience, and expanding internationally.

• Jake Leach, with 21 years at the company, has become CEO, succeeding Kevin Sayer.

• Emphasis on scalable operations to support global growth and manufacturing expansion.

• Mission remains personal, with many employees using the product themselves.

Market landscape and growth opportunities

• Diabetes prevalence is rising, with 600 million diagnosed globally, projected to reach 853 million by 2050.

• Only 2% of the diabetes population currently uses CGM, indicating significant untapped market potential.

• Coverage for CGM has expanded, but awareness and adoption lag, especially among those already covered.

• Type 2 basal and non-insulin segments present major growth opportunities due to low penetration.

Product innovation and technology advancements

• Launched Dexcom G7 15 Day system, improving wear time and efficiency.

• SmartBasal enables remote insulin titration with physician oversight, rolling out in select clinics.

• Enhanced digital experience with My Dexcom account and AI-driven support tools.

• G8 sensor to launch soon, promising highest accuracy and smallest form factor.